Cargando…

Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting

OBJECTIVE: This study tried to observe additional benefit of agomelatine (AGO) treatment for major depressive disorder (MDD) in routine practice. METHODS: Retrospective chart review (n = 63) was conducted for additional benefit of combination with or switching to AGO in MDD patients without full rem...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kyung Ho, Han, Tae Sun, Han, Changsu, Bahk, Won-Myong, Lee, Soo-Jung, Patkar, Ashwin A., Masand, Prakash S., Pae, Chi-Un
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335900/
https://www.ncbi.nlm.nih.gov/pubmed/37424426
http://dx.doi.org/10.9758/cpn.23.1060
_version_ 1785071093585805312
author Lee, Kyung Ho
Han, Tae Sun
Han, Changsu
Bahk, Won-Myong
Lee, Soo-Jung
Patkar, Ashwin A.
Masand, Prakash S.
Pae, Chi-Un
author_facet Lee, Kyung Ho
Han, Tae Sun
Han, Changsu
Bahk, Won-Myong
Lee, Soo-Jung
Patkar, Ashwin A.
Masand, Prakash S.
Pae, Chi-Un
author_sort Lee, Kyung Ho
collection PubMed
description OBJECTIVE: This study tried to observe additional benefit of agomelatine (AGO) treatment for major depressive disorder (MDD) in routine practice. METHODS: Retrospective chart review (n = 63) was conducted for additional benefit of combination with or switching to AGO in MDD patients without full remission. The primary endpoint was the mean change of Clinical Global Impression-Clinical Benefit (CGI-CB) total scores from baseline to the endpoint. Additional secondary endpoints were also collected. RESULTS: The changes of CGI-CB (Z = −3.073, p = 0.002) and Montgomery-Åsberg Depression Rating Scale (Z = −3.483, p < 0.001) total scores were significantly decreased from baseline to the endpoint, respectively. At the endpoint, the remission rate was 22.6% (n = 18) and 28.6% of patient had improvement in CGI-CB total scores at the endpoint. No significant adverse events were observed. CONCLUSION: This study has shown additional benefit of AGO treatment as combination or switching agent for MDD patients without full remission in routine practice. However, adequately-powered and well-controlled studies are necessary for generalization of the present findings.
format Online
Article
Text
id pubmed-10335900
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Korean College of Neuropsychopharmacology
record_format MEDLINE/PubMed
spelling pubmed-103359002023-08-31 Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting Lee, Kyung Ho Han, Tae Sun Han, Changsu Bahk, Won-Myong Lee, Soo-Jung Patkar, Ashwin A. Masand, Prakash S. Pae, Chi-Un Clin Psychopharmacol Neurosci Brief Report OBJECTIVE: This study tried to observe additional benefit of agomelatine (AGO) treatment for major depressive disorder (MDD) in routine practice. METHODS: Retrospective chart review (n = 63) was conducted for additional benefit of combination with or switching to AGO in MDD patients without full remission. The primary endpoint was the mean change of Clinical Global Impression-Clinical Benefit (CGI-CB) total scores from baseline to the endpoint. Additional secondary endpoints were also collected. RESULTS: The changes of CGI-CB (Z = −3.073, p = 0.002) and Montgomery-Åsberg Depression Rating Scale (Z = −3.483, p < 0.001) total scores were significantly decreased from baseline to the endpoint, respectively. At the endpoint, the remission rate was 22.6% (n = 18) and 28.6% of patient had improvement in CGI-CB total scores at the endpoint. No significant adverse events were observed. CONCLUSION: This study has shown additional benefit of AGO treatment as combination or switching agent for MDD patients without full remission in routine practice. However, adequately-powered and well-controlled studies are necessary for generalization of the present findings. Korean College of Neuropsychopharmacology 2023-08-31 2023-08-31 /pmc/articles/PMC10335900/ /pubmed/37424426 http://dx.doi.org/10.9758/cpn.23.1060 Text en Copyright© 2023, Korean College of Neuropsychopharmacology https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Lee, Kyung Ho
Han, Tae Sun
Han, Changsu
Bahk, Won-Myong
Lee, Soo-Jung
Patkar, Ashwin A.
Masand, Prakash S.
Pae, Chi-Un
Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
title Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
title_full Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
title_fullStr Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
title_full_unstemmed Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
title_short Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
title_sort additional clinical benefit of agomelatine treatment for major depressive disorder in naturalistic treatment setting
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335900/
https://www.ncbi.nlm.nih.gov/pubmed/37424426
http://dx.doi.org/10.9758/cpn.23.1060
work_keys_str_mv AT leekyungho additionalclinicalbenefitofagomelatinetreatmentformajordepressivedisorderinnaturalistictreatmentsetting
AT hantaesun additionalclinicalbenefitofagomelatinetreatmentformajordepressivedisorderinnaturalistictreatmentsetting
AT hanchangsu additionalclinicalbenefitofagomelatinetreatmentformajordepressivedisorderinnaturalistictreatmentsetting
AT bahkwonmyong additionalclinicalbenefitofagomelatinetreatmentformajordepressivedisorderinnaturalistictreatmentsetting
AT leesoojung additionalclinicalbenefitofagomelatinetreatmentformajordepressivedisorderinnaturalistictreatmentsetting
AT patkarashwina additionalclinicalbenefitofagomelatinetreatmentformajordepressivedisorderinnaturalistictreatmentsetting
AT masandprakashs additionalclinicalbenefitofagomelatinetreatmentformajordepressivedisorderinnaturalistictreatmentsetting
AT paechiun additionalclinicalbenefitofagomelatinetreatmentformajordepressivedisorderinnaturalistictreatmentsetting